Skip to content

Venture

LOGO 7-01

Affiliations

New York University

Technologies

Therapeutic

Indication

Basic Research

Clinical Research

Clinical Trials

Drug Discovery

Oncology

Orphan Diseases

We are developing an enzyme inhibitor with pico-­‐molar binding affinity and minimal toxicity as a once daily, oral therapeutic for the treatment of triple-­‐negative breast cancer.

Nanomedics LLC Team:

Michael Isaacman

Andrew Mahon